Summary of Study ST002295
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001307. The data can be accessed directly via it's Project DOI: 10.21228/M8S124 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002295 |
| Study Title | Metabolic impact of anticancer drugs Pd2Spermine and Cisplatin on the lipophilic metabolome of liver from cell-derived xenograft mouse model of Triple-Negative Breast Cancer (part 2) |
| Study Type | NMR-based metabolomics |
| Study Summary | Platinum (Pt(II)) drugs, e.g. cisplatin (cDDP), are some of the most used chemotherapeutic agents, yet tumor acquired resistance and high toxicity are still current drawbacks. Palladium (Pd(II))-complexes are alternatives due to similar metal coordination and promising cytotoxic properties. Metabolomics can measure the metabolic response of drug-exposed tissues, unveiling insight into drug mechanisms and new markers of drug efficacy/toxicity. The present 1H NMR metabolomics study aims to characterize the in vivo response of the impact of a Pd(II)-complex with polyamine spermine (Pd2Spm), compared to cDDP, on lipophilic metabolism of liver from cell-derived xenograft mouse model of Triple-Negative Breast Cancer. |
| Institute | University of Aveiro |
| Department | Department of Chemistry and CICECO-Aveiro Institute of Materials |
| Laboratory | Metabolomics from Ana M. Gil |
| Last Name | Carneiro |
| First Name | Tatiana João |
| Address | Campus Universitário de Santiago, Aveiro, Aveiro, 3810-193, Portugal |
| tatiana.joao@ua.pt | |
| Phone | +351 234 370 200 |
| Submit Date | 2022-09-14 |
| Num Groups | 3 |
| Total Subjects | 22 |
| Num Females | 22 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | fid |
| Analysis Type Detail | NMR |
| Release Date | 2022-12-15 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR002393 |
| Treatment Summary: | At day 25 post-implantation, 8 animals were randomly chosen into three groups to receive the treatment with either (i) vehicle (phosphate-buffered saline, PBS) - controls, (ii) cDDP (2 mg/kg/day), or (iii) Pd2Spm (5 mg/kg/day), via intraperitoneal injection, during five consecutive days. Two control animals were excluded from the study since they developed ulcerated tumors (at day 28 post-implantation) and needed to be prematurely euthanized. |
| Treatment Route: | Intraperitoneal injection |
| Treatment Dosevolume: | 500 microliters |
| Treatment Vehicle: | PBS (phosphate-buffered saline solution) |
